Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Running, not enrolling · Phase 1

Conditions studied: Lymphoma, B-Cell

In brief

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.

Key facts

Study ID

NCT04884035

Run by

Celgene

People needed

224

Starts

2021-09-15

Expected to finish

2028-12-01

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must satisfy the following criteria to be enrolled in the study:
• Is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• Participant has histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated, a-BCL according to 2016 WHO classification.
• Participant has International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2. For the CELMoD and polatuzumab-R-CHP cohort, the subject must also have IPI score 0 to 5 in Part 2A and IPI 2 to 5 in Part 2B.
• Participants must have measurable disease defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).
• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Participants must have the following laboratory values:
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without growth factor support for 7 days (14 days if peg-G-CSF)
• Hemoglobin (Hb) ≥ 8 g/dL
• Platelets (PLT) ≥ 75 x 109/L or ≥ 50 x 109/L in case of documented bone marrow involvement (>50% or tumor cells), without transfusion for 7 days
• Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamate pyruvic transaminase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN). In the case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ≤ 5.0 x ULN.
• Serum total bilirubin ≤ 2.0 mg/dL except in cases of Gilbert's syndrome, then ≤ 5.0 mg/dl. Subjects receiving polatuzumab vedotin must have serum total bilirubin < 1.5 × ULN (26 μmol/L) (corresponding to mild degree as per National Cancer Institute Organ Dysfunction Working Group [NCI ODWG] criteria) except in cases of Gilbert's syndrome, then ≤ 3.0 mg/dl (51 μmol/L).
• Estimated serum creatinine clearance (CrCl) of ≥ 50 mL/min using the modification of diet in renal disease (MDRD) formula.
• All participants must:
• Have an understanding that the study drug could have a potential teratogenic risk.
• Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in Clinical trials.
• Females of childbearing potential (FCBP) must:
• a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy.
• Male participants must:
• Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.

You may not qualify if…

• The presence of any of the following will exclude a participant from enrollment:
• Any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
• Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.
• Any other subtype of lymphoma.
• Documented or suspected CNS involvement by lymphoma.
• Persistent diarrhea or malabsorption ≥ Grade 2 (NCI CTCAE v5.0), despite medical management.
• Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).
• Subjects with a history of progressive multifocal leukoencephalopathy.
• Chronic systemic immunosuppressive therapy or corticosteroids
• Impaired cardiac function or clinically significant cardiac disease, including any of the following:
• a. Left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)
• Major surgery ≤ 2 weeks prior to starting CC-220 or CC-99282; participant must have recovered from any clinically significant effects of recent surgery.
• Any condition causing inability to swallow tablets.
• Known seropositivity for or active viral infection with human immunodeficiency virus (HIV)
• Known chronic active hepatitis B (hepatitis B virus surface antigen [HBsAg] positive and/or hepatitis B core antibody [anti-HBc] positive with viral DNA positive) or C (positive serology requiring treatment and/or with evidence of liver damage) infection
• History of other malignancy, unless being free of the disease for ≥ 3 years; exceptions to the ≥ 3-year time limit include history of the following:
• Localized nonmelanoma skin cancer
• Carcinoma in situ of the cervix
• Carcinoma in situ of the breast
• Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis [TNM] staging system) or prostate cancer that has been treated with curative intent.
• Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or polatuzumab vedotin.
• Known hypersensitivity to any component of CHOP/CHP regimen.
• Known allergy to thalidomide, pomalidomide, or lenalidomide.

Where it is running

• Local Institution - 162 — Birmingham, Alabama, United States
• Local Institution - 154 — Scottsdale, Arizona, United States
• Local Institution - 169 — Duarte, California, United States
• Local Institution - 160 — Jacksonville, Florida, United States
• Local Institution - 161 — Marietta, Georgia, United States
• Local Institution - 159 — Kansas City, Kansas, United States
• Local Institution - 166 — Wichita, Kansas, United States
• Local Institution - 152 — Rochester, Minnesota, United States
• Local Institution - 163 — Saint Louis Park, Minnesota, United States
• Local Institution - 151 — Omaha, Nebraska, United States
• Local Institution - 170 — Charlotte, North Carolina, United States
• Local Institution - 164 — Winston-Salem, North Carolina, United States
• Local Institution - 155 — Houston, Texas, United States
• Local Institution - 168 — Murray, Utah, United States
• Local Institution - 171 — St. George, Utah, United States
• Local Institution - 501 — Adelaide, South Australia, Australia
• Local Institution - 503 — Perth, Australia
• Local Institution - 702 — Athens, Greece
• Local Institution - 704 — Athens, Greece
• Local Institution - 701 — Athens, Greece
• Local Institution - 700 — Thessaloniki, Greece
• Local Institution - 605 — Skórzewo, Greater Poland Voivodeship, Poland
• Local Institution - 601 — Gdansk, Poland
• Local Institution - 600 — Krakow, Poland
• Local Institution - 603 — Słomniki, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.